Concurrent Stage III Unresectable Duodenal Adenocarcinoma and Metastatic Gastrointestinal Stromal Tumor Treated With Combination of Imatinib and mFOLFIRI

Amith Rao; Rohit Rao; Megan K Taylor; Mohammad Khreiss; Junaid Arshad

doi:10.7759/cureus.58248

Concurrent Stage III Unresectable Duodenal Adenocarcinoma and Metastatic Gastrointestinal Stromal Tumor Treated With Combination of Imatinib and mFOLFIRI

Cureus. 2024 Apr 14;16(4):e58248. doi: 10.7759/cureus.58248. eCollection 2024 Apr.

Authors

Amith Rao¹, Rohit Rao², Megan K Taylor³, Mohammad Khreiss⁴, Junaid Arshad⁵

Affiliations

¹ Department of Internal Medicine, Banner Health, Tucson, USA.
² Department of Internal Medicine, University Hospitals Cleveland Medical Center, Cleveland, USA.
³ Department of Internal Medicine, University of Arizona College of Medicine, Tucson, USA.
⁴ Department of Surgical Oncology, University of Arizona College of Medicine, Tucson, USA.
⁵ Department of Medical Oncology, University of Arizona Cancer Center, Tucson, USA.

Abstract

Cases of concurrent duodenal adenocarcinoma and gastrointestinal stromal tumors (GISTs) are rare, and only a few have been reported. While some cases of other synchronous primary tumors with GIST have been reported, no shared mutations have been consistently found, creating challenges in selecting chemotherapy in cases of inoperable tumors. Here, we presented a case of a stage IIIA locally advanced/unresectable duodenal adenocarcinoma with concurrent metastatic small bowel GIST successfully being treated with combined imatinib and modified folinic acid, 5-fluorouracil, and irinotecan (mFOLFIRI) regimen.

Keywords: duodenal adenocarcinoma; gastrointestinal stromal tumor (gist); imatinib; mfolfiri; tyrosine kinase inhibitors (tki).

Publication types

Case Reports